Novelgen
Find Us
← Back to list
FDA again turns back Capricor Duchenne cell therapy

FDA again turns back Capricor Duchenne cell therapy

BioPharma DiveGwendolyn WuNovember 21, 2026
In an unusual statement, the FDA accused Capricor of serious data integrity violations that compromised its study findings and led to deramiocel s second rejection since 2025.
Read original article
← Back to list